Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Hellgren, Karin ; Dreyer, Lene ; Arkema, Elizabeth V ; Glintborg, Bente ; Jacobsson, Lennart T H ; Kristensen, Lars-Erik ; Feltelius, Nils ; Hetland, Merete Lund ; Askling, Johan ; ARTIS Study Group, For the DANBIO Study Group. / Cancer risk in patients with spondyloarthritis treated with TNF inhibitors : a collaborative study from the ARTIS and DANBIO registers. I: Annals of the Rheumatic Diseases. 2017 ; Bind 76, Nr. 1. s. 105-111.

Bibtex

@article{3b302826011c451b87dfa5fce4f699e8,
title = "Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers",
abstract = "BACKGROUND: Safety data on cancer risks following tumour necrosis factor α inhibitors (TNFi) in patients with spondyloarthritis (SpA) (here defined as ankylosing spondylitis (AS), undifferentiated spondarthropaties (SpA UNS), psoriatic arthritis (PsA)) are scarce. Our objective was to assess risks for cancer overall and for common subtypes in patients with SpA treated with TNFi compared with TNFi-na{\"i}ve patients with SpA and to the general population.METHODS: From the Swedish (Anti-Rheumatic Therapy in Sweden (ARTIS)) and Danish (DANBIO) biologics registers, we assembled 8703 (ARTIS=5448, DANBIO=3255) patients with SpA initiating a first TNFi 2001-2011. From the Swedish National Patient and Population Registers we assembled a TNFi-na{\"i}ve SpA cohort (n=28,164) and a Swedish age-matched and sex-matched general population comparator cohort (n=131 687). We identified incident cancers by linkage with the nationwide Swedish and Danish Cancer Registers 2001-2011, and calculated age-standardised and sex-standardised incidence ratios as measures of relative risk (RR).RESULTS: Based on 1188 cancers among the TNFi-na{\"i}ve patients with SpA, RR of cancer overall was 1.1 (95{\%} CI 1.0 to 1.2). Based on 147 cancers among TNFi initiators with SpA, RR versus TNFi-na{\"i}ve was 0.8 (95{\%} CI 0.7 to 1.0) and results were similar for AS and PsA when analysed separately. Site-specific cancer RRs: prostate 0.5 (95{\%} CI 0.3 to 0.8), lung 0.6 (95{\%} CI 0.3 to 1.3), colorectal 1.0 (95{\%} CI 0.5 to 2.0), breast 1.3 (95{\%} CI 0.9 to 2.0), lymphoma 0.8 (95{\%} CI 0.4 to 1.8) and melanoma 1.4 (95{\%} CI 0.7 to 2.6).CONCLUSIONS: In patients with SpA, treatment with TNFi was not associated with increased risks of cancer, neither overall nor for the six most common cancer types.",
keywords = "Adalimumab, Adult, Antibodies, Monoclonal, Antirheumatic Agents, Arthritis, Psoriatic, Breast Neoplasms, Certolizumab Pegol, Cohort Studies, Colorectal Neoplasms, Denmark, Etanercept, Female, Humans, Incidence, Infliximab, Lung Neoplasms, Lymphoma, Male, Melanoma, Middle Aged, Neoplasms, Prostatic Neoplasms, Registries, Risk Assessment, Spondylitis, Ankylosing, Sweden, Tumor Necrosis Factor-alpha, Journal Article",
author = "Karin Hellgren and Lene Dreyer and Arkema, {Elizabeth V} and Bente Glintborg and Jacobsson, {Lennart T H} and Lars-Erik Kristensen and Nils Feltelius and Hetland, {Merete Lund} and Johan Askling and {ARTIS Study Group, For the DANBIO Study Group}",
note = "COPECARE",
year = "2017",
month = "1",
doi = "10.1136/annrheumdis-2016-209270",
language = "English",
volume = "76",
pages = "105--111",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "B M J Group",
number = "1",

}

RIS

TY - JOUR

T1 - Cancer risk in patients with spondyloarthritis treated with TNF inhibitors

T2 - a collaborative study from the ARTIS and DANBIO registers

AU - Hellgren, Karin

AU - Dreyer, Lene

AU - Arkema, Elizabeth V

AU - Glintborg, Bente

AU - Jacobsson, Lennart T H

AU - Kristensen, Lars-Erik

AU - Feltelius, Nils

AU - Hetland, Merete Lund

AU - Askling, Johan

AU - ARTIS Study Group, For the DANBIO Study Group

N1 - COPECARE

PY - 2017/1

Y1 - 2017/1

N2 - BACKGROUND: Safety data on cancer risks following tumour necrosis factor α inhibitors (TNFi) in patients with spondyloarthritis (SpA) (here defined as ankylosing spondylitis (AS), undifferentiated spondarthropaties (SpA UNS), psoriatic arthritis (PsA)) are scarce. Our objective was to assess risks for cancer overall and for common subtypes in patients with SpA treated with TNFi compared with TNFi-naïve patients with SpA and to the general population.METHODS: From the Swedish (Anti-Rheumatic Therapy in Sweden (ARTIS)) and Danish (DANBIO) biologics registers, we assembled 8703 (ARTIS=5448, DANBIO=3255) patients with SpA initiating a first TNFi 2001-2011. From the Swedish National Patient and Population Registers we assembled a TNFi-naïve SpA cohort (n=28,164) and a Swedish age-matched and sex-matched general population comparator cohort (n=131 687). We identified incident cancers by linkage with the nationwide Swedish and Danish Cancer Registers 2001-2011, and calculated age-standardised and sex-standardised incidence ratios as measures of relative risk (RR).RESULTS: Based on 1188 cancers among the TNFi-naïve patients with SpA, RR of cancer overall was 1.1 (95% CI 1.0 to 1.2). Based on 147 cancers among TNFi initiators with SpA, RR versus TNFi-naïve was 0.8 (95% CI 0.7 to 1.0) and results were similar for AS and PsA when analysed separately. Site-specific cancer RRs: prostate 0.5 (95% CI 0.3 to 0.8), lung 0.6 (95% CI 0.3 to 1.3), colorectal 1.0 (95% CI 0.5 to 2.0), breast 1.3 (95% CI 0.9 to 2.0), lymphoma 0.8 (95% CI 0.4 to 1.8) and melanoma 1.4 (95% CI 0.7 to 2.6).CONCLUSIONS: In patients with SpA, treatment with TNFi was not associated with increased risks of cancer, neither overall nor for the six most common cancer types.

AB - BACKGROUND: Safety data on cancer risks following tumour necrosis factor α inhibitors (TNFi) in patients with spondyloarthritis (SpA) (here defined as ankylosing spondylitis (AS), undifferentiated spondarthropaties (SpA UNS), psoriatic arthritis (PsA)) are scarce. Our objective was to assess risks for cancer overall and for common subtypes in patients with SpA treated with TNFi compared with TNFi-naïve patients with SpA and to the general population.METHODS: From the Swedish (Anti-Rheumatic Therapy in Sweden (ARTIS)) and Danish (DANBIO) biologics registers, we assembled 8703 (ARTIS=5448, DANBIO=3255) patients with SpA initiating a first TNFi 2001-2011. From the Swedish National Patient and Population Registers we assembled a TNFi-naïve SpA cohort (n=28,164) and a Swedish age-matched and sex-matched general population comparator cohort (n=131 687). We identified incident cancers by linkage with the nationwide Swedish and Danish Cancer Registers 2001-2011, and calculated age-standardised and sex-standardised incidence ratios as measures of relative risk (RR).RESULTS: Based on 1188 cancers among the TNFi-naïve patients with SpA, RR of cancer overall was 1.1 (95% CI 1.0 to 1.2). Based on 147 cancers among TNFi initiators with SpA, RR versus TNFi-naïve was 0.8 (95% CI 0.7 to 1.0) and results were similar for AS and PsA when analysed separately. Site-specific cancer RRs: prostate 0.5 (95% CI 0.3 to 0.8), lung 0.6 (95% CI 0.3 to 1.3), colorectal 1.0 (95% CI 0.5 to 2.0), breast 1.3 (95% CI 0.9 to 2.0), lymphoma 0.8 (95% CI 0.4 to 1.8) and melanoma 1.4 (95% CI 0.7 to 2.6).CONCLUSIONS: In patients with SpA, treatment with TNFi was not associated with increased risks of cancer, neither overall nor for the six most common cancer types.

KW - Adalimumab

KW - Adult

KW - Antibodies, Monoclonal

KW - Antirheumatic Agents

KW - Arthritis, Psoriatic

KW - Breast Neoplasms

KW - Certolizumab Pegol

KW - Cohort Studies

KW - Colorectal Neoplasms

KW - Denmark

KW - Etanercept

KW - Female

KW - Humans

KW - Incidence

KW - Infliximab

KW - Lung Neoplasms

KW - Lymphoma

KW - Male

KW - Melanoma

KW - Middle Aged

KW - Neoplasms

KW - Prostatic Neoplasms

KW - Registries

KW - Risk Assessment

KW - Spondylitis, Ankylosing

KW - Sweden

KW - Tumor Necrosis Factor-alpha

KW - Journal Article

U2 - 10.1136/annrheumdis-2016-209270

DO - 10.1136/annrheumdis-2016-209270

M3 - Journal article

VL - 76

SP - 105

EP - 111

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 1

ER -

ID: 50634090